Biological Markers in Retinal Vasculitis
Identification of Biological Markers in Retinal Vasculitis
Identification of Biological Markers in Retinal Vasculitis
Sponsor study identifier
Secondary identifiers
observational
200
1 country
1
Study Start
December 6, 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 19, 2006
Date type not reportedThis date has not been verified as actual or estimated.
This study will look for biological markers of primary retinal vasculitis that can be useful in understanding what causes the disease. It will evaluate its progression, and develop and monitor treatments. Biological markers are substances (e.g., chemicals called cytokines and chemokines or antibodies) that are associated with a disease or condition such as retinal vasculitis. Retinal vasculitis is an inflammation of blood vessels in the retina that can cause retinal damage and subsequent loss of vision. It can occur by itself (primary retinal vasculitis), or it can be part of a systemic vascular disease. The study will evaluate patients with primary retinal vasculitis and compare the findings with those of two other groups of patients with retinal vasculitis patients with Behcet's syndrome and HIV-infected patients undergoing HAART therapy. Patients over 10 years of age with sight-threatening retinal vasculitis may be eligible for this study. (page 6 of the protocol, under #4 Study Design and Methods, says the age range is 2 years old and above; page 10, under #5 Participant Inclusion and Exclusion Criteria, says initial enrollment will include all patients over the age of 10 years). Upon entering the study, participants will have about 10 teaspoons of blood withdrawn from an arm vein through a needle and again 6 months and 12 months later. The blood samples will be analyzed for cytokines, chemokines or adhesion molecules, certain types of antibodies, and infectious agents.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 19, 2006
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 6, 2002
Date type not reportedThis date has not been verified as actual or estimated.
December 9, 2002
Actual (reported)December 10, 2002
Actual (reported)September 19, 2006
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
National Eye Institute (NEI)
Bethesda, Maryland, 20892, United States
Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996 Aug 1;184(2):387-96. doi: 10.1084/jem.184.2.387.
First Submitted
December 9, 2002
First Posted
December 10, 2002
Study Start
December 6, 2002
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
September 19, 2006
Date type not reportedThis date has not been verified as actual or estimated.
Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)
Last Updated
July 2, 2017
Record last verified: 2006-09-19
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: